October 28, 2013JAMA Neurology
New Oral Anticoagulants and the Risk of Intracranial Hemorrhage
Key result
Novel oral anticoagulants significantly reduced the risk of intracranial hemorrhage compared to all comparators (OR 0.49; 95% CI 0.36-0.65).
Why the study?
Do novel oral anticoagulants reduce the risk of intracranial hemorrhage compared to comparators in patients with atrial fibrillation?
Population
57,491 patients with atrial fibrillation from 6 randomized trials
Comparison
Novel oral anticoagulants vs Comparators (not specified in abstract)
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
Supports preferential use of novel oral anticoagulants in atrial fibrillation to reduce intracranial hemorrhage; confirms benefit versus comparators in Level 1 evidence.
Study Design
Type
Meta-Analysis (n=57,491)
Structured PICO
Do novel oral anticoagulants reduce the risk of intracranial hemorrhage compared to comparators in patients with atrial fibrillation?
P
Population
57,491 patients from 6 randomized trials comparing novel oral anticoagulants versus comparators for stroke prevention in atrial fibrillation.
I
Intervention
Novel oral anticoagulants (NOACs: dabigatran, rivaroxaban, apixaban)
C
Comparator
Comparators (not specified in abstract)
O
Outcome
Intracranial hemorrhage (ICH) eventssafety
Main Result
Odds Ratio: 0.49 (95% CI 0.36–0.65)
Novel oral anticoagulants are uniformly associated with a reduced risk of intracranial hemorrhage compared to comparators in patients with atrial fibrillation.
Cite This Study
Chatterjee et al. (2013) conducted a meta-analysis in Atrial fibrillation (n=57,491). Novel oral anticoagulants (NOACs) vs. All comparators was evaluated on Intracranial hemorrhage events (OR 0.49, 95% CI 0.36-0.65). Novel oral anticoagulants significantly reduced the risk of intracranial hemorrhage compared to all comparators (OR 0.49; 95% CI 0.36-0.65).